Cardiff Oncology Net Debt Growth & History (CRDF)
Cardiff Oncology's net debt was −$16.6M for fiscal 2025.
View full Cardiff Oncology company overviewCardiff Oncology annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$16.6M | $33.3M | — |
| 2024 | 2024-12-31 | −$49.9M | −$30.4M | — |
| 2023 | 2023-12-31 | −$19.5M | −$5.9M | — |
| 2022 | 2022-12-31 | −$13.6M | −$4.8M | — |
| 2021 | 2021-12-31 | −$8.8M | $121.3M | — |
| 2020 | 2020-12-31 | −$130.1M | −$121.6M | — |
| 2019 | 2019-12-31 | −$8.5M | $3.0M | — |
| 2018 | 2018-12-31 | −$11.5M | −$3.2M | — |
| 2017 | 2017-12-31 | −$8.2M | −$8.5M | — |
| 2016 | 2016-12-31 | $261,265 | $56.5M | — |
| 2015 | 2015-12-31 | −$56.2M | −$42.0M | — |
| 2014 | 2014-12-31 | −$14.2M | — | — |
Cardiff Oncology quarterly net debt
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$8.7M | $859,000 | — |
| Q1 2026 | 2026-03-31 | −$7.9M | $14.8M | — |
| Q4 2025 | 2025-12-31 | −$16.6M | $33.3M | — |
| Q3 2025 | 2025-09-30 | −$9.1M | $2.2M | — |
| Q2 2025 | 2025-06-30 | −$9.6M | $14.1M | — |
| Q1 2025 | 2025-03-31 | −$22.7M | −$6.1M | — |
| Q4 2024 | 2024-12-31 | −$49.9M | −$30.4M | — |
| Q3 2024 | 2024-09-30 | −$11.4M | $1.6M | — |
| Q2 2024 | 2024-06-30 | −$23.7M | −$6.7M | — |
| Q1 2024 | 2024-03-31 | −$16.7M | −$4.2M | — |
| Q4 2023 | 2023-12-31 | −$19.5M | −$5.9M | — |
| Q3 2023 | 2023-09-30 | −$12.9M | $2.9M | — |
| Q2 2023 | 2023-06-30 | −$16.9M | $1.1M | — |
| Q1 2023 | 2023-03-31 | −$12.4M | $4.5M | — |
| Q4 2022 | 2022-12-31 | −$13.6M | −$4.8M | — |
| Q3 2022 | 2022-09-30 | −$15.9M | −$6.0M | — |
| Q2 2022 | 2022-06-30 | −$18.0M | −$7.8M | — |
| Q1 2022 | 2022-03-31 | −$16.9M | −$2.9M | — |
| Q4 2021 | 2021-12-31 | −$8.8M | $121.3M | — |
| Q3 2021 | 2021-09-30 | −$9.9M | $25.4M | — |
| Q2 2021 | 2021-06-30 | −$10.2M | $16.3M | — |
| Q1 2021 | 2021-03-31 | −$14.0M | −$6.3M | — |
| Q4 2020 | 2020-12-31 | −$130.1M | −$121.6M | — |
| Q3 2020 | 2020-09-30 | −$35.3M | −$28.2M | — |
| Q2 2020 | 2020-06-30 | −$26.4M | −$17.8M | — |
| Q1 2020 | 2020-03-31 | −$7.8M | $1.3M | — |
| Q4 2019 | 2019-12-31 | −$8.5M | $3.0M | — |
| Q3 2019 | 2019-09-30 | −$7.1M | $8.0M | — |
| Q2 2019 | 2019-06-30 | −$8.7M | $9.8M | — |
| Q1 2019 | 2019-03-31 | −$9.0M | −$3.5M | — |
| Q4 2018 | 2018-12-31 | −$11.5M | −$3.2M | — |
| Q3 2018 | 2018-09-30 | −$15.1M | −$7.6M | — |
| Q2 2018 | 2018-06-30 | −$18.5M | −$10.7M | — |
| Q1 2018 | 2018-03-31 | −$5.5M | −$8.0M | — |
| Q4 2017 | 2017-12-31 | −$8.2M | −$8.5M | — |
| Q3 2017 | 2017-09-30 | −$7.4M | −$9.0M | — |
| Q2 2017 | 2017-06-30 | −$7.8M | −$6.2M | — |
| Q1 2017 | 2017-03-31 | $2.5M | $52.1M | — |
| Q4 2016 | 2016-12-31 | $261,265 | $56.5M | — |
| Q3 2016 | 2016-09-30 | $1.5M | $64.1M | — |
| Q2 2016 | 2016-06-30 | −$1.6M | $26.8M | — |
| Q1 2016 | 2016-03-31 | −$49.6M | −$17.6M | — |
| Q4 2015 | 2015-12-31 | −$56.2M | −$42.0M | — |
| Q3 2015 | 2015-09-30 | −$62.6M | — | — |
| Q2 2015 | 2015-06-30 | −$28.4M | — | — |
| Q1 2015 | 2015-03-31 | −$32.0M | — | — |
| Q4 2014 | 2014-12-31 | −$14.2M | — | — |
| Q3 2013 | 2013-09-30 | −$27.4M | — | — |
| Q2 2013 | 2013-06-30 | −$8.1M | — | — |
Cardiff Oncology net debt trends
Over the last five fiscal years, Cardiff Oncology's net debt increased from −$130.1M to −$16.6M, a change of $113.5M. The latest reported quarter, Q2 2026, shows −$8.7M.
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cardiff Oncology source filings ↗